Research on Polymeric Adriamycin-bonded Nanocapsules Patented

The company’s patent for the “High-molecular Adriamycin-bonded nanocapsule with targeted function and its preparation method” invented by the researcher of the Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, etc., was recently awarded a national invention. Licensing.

Doxorubicin is an anthracycline antitumor antibiotic that is mainly used in the treatment of acute leukemia, malignant lymphoma, liver cancer, lung cancer, gastric cancer, esophageal cancer, breast cancer, cervical cancer, and bladder cancer. At present, clinical dosing is mostly intravenous drip, but doxorubicin does not pass through the blood-brain barrier, and the drug is rapidly distributed throughout the body after intravenous injection. It has serious toxic and side effects on the bone marrow and heart. Although the dose is large, it can The proportion of patients reaching the site of the disease is very low.

Jing Weibin's research group proposed the use of biodegradable polymers as carriers for drug delivery. Chemical bonding methods are used to chemically bond drug molecules to macromolecules, thereby overcoming the initial burst problem of traditional drug-loaded micelles. Based on this research, they further bonded the targeting molecules to the outer layer of the nanomicelles so that they could act as "probes" to find cancerous cells and achieve targeted drug delivery. The invention developed a new pharmaceutical dosage form of adriamycin, which can improve the efficacy of the original drug and reduce the toxic and side effects of the original drug.

Cpap Mask

Cpap Mask,Full-Face Cpap Mask,Reusable Cpap Masks,Reusable Full-Face Mask

Shaoxing Jenston Medical Products Co., Ltd. , https://www.sxjcmed.com

Posted on